TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31533391

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg tranexamic acid before upper tourniquet and after closure of incision, combined with flexion position of hip (30° to 45°) and knee (60° for 70°)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15 mg/kg tranexamic acid injected before loosening tourniquet
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline before loosening tourniquet
Number of subjects: 90
Study: 27868259

Group type: EXPERIMENTAL
Intervention: 3-day workshop
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 112
Study: 25891054

Group type: EXPERIMENTAL
Intervention: Family‐individual‐school‐based comprehensive intervention
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1446
Study: 22385210

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 21336673

Group type: EXPERIMENTAL
Intervention: Participatory return-to-work program
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 163
Study: 19218297

Group type: EXPERIMENTAL
Intervention: Robot therapy with physiotherapy (10 sessions, more than 5000 movements)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Robot therapy with physiotherapy
Number of subjects: 10
Study: 17560876

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus provisional glycoprotein IIb/IIIa inhibitor
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Unfractionated heparin plus planned glycoprotein IIb/IIIa inhibitor
Number of subjects: 6010
Study: 15518172

Group type: EXPERIMENTAL
Intervention: Nigerose
Number of subjects: 0
Study: 11699981

Group type: EXPERIMENTAL
Intervention: Sealants
Number of subjects: 9
Study: 9600478

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 390
Study: 8273794

Group type: EXPERIMENTAL
Intervention: 4 x/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 5 x/day therapy of CBS (108 mg), tetracycline HCl (250 mg), and metronidazole (200 mg)
Number of subjects: 423
Study: 2537217

Group type: EXPERIMENTAL
Intervention: Trandolapril (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 24, 32 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 4983855

Group type: EXPERIMENTAL
Intervention: Carbenicillin plus gentamicin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ampicillin or no antibiotic
Number of subjects: 67
Study: 31626835

Group type: EXPERIMENTAL
Intervention: Group treatment program focused on parenting skills (10 weekly sessions)
Number of subjects: 36
Study: 31222797

Group type: EXPERIMENTAL
Intervention: Progressive disease due to lymphadenopathy (Ly)
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Progressive disease due to increasing absolute lymphocyte count (ALC)
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Progressive disease due to lymphadenopathy (Ly) in unfit patients
Number of subjects: 2159

Group type: EXPERIMENTAL
Intervention: Progressive disease due to increasing absolute lymphocyte count (ALC) in unfit patients
Number of subjects: 2159
Study: 25312405

Group type: EXPERIMENTAL
Intervention: Mineralocorticoids
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vasodilators
Number of subjects: 70
Study: 23627374

Group type: EXPERIMENTAL
Intervention: MCAT + CM (collagen matrix)
Number of subjects: 22

Group type: COMPARATOR
Intervention: MCAT + CTG (palatal connective tissue graft)
Number of subjects: 22
Study: 21301920

Group type: COMPARATOR
Intervention: Methylprednisolone alone (MP group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Methylprednisolone in combination with azathioprine (MP + Aza group)
Number of subjects: 22
Study: 19156159

Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D(3) fortified milk (400 ml per day, approximately 1000 mg of calcium and 800 IU of vitamin D(3))
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no additional fortified milk)
Number of subjects: 140
Study: 17474812

Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive outreach community treatment, family psychoeducation, social skills training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 50
Study: 15456995

Group type: EXPERIMENTAL
Intervention: History of chronic bronchitis or emphysema (CB/E)
Number of subjects: 17698

Group type: COMPARATOR
Intervention: Other lung diseases (not specified)
Number of subjects: 17698
Study: 11250978

Group type: EXPERIMENTAL
Intervention: ACE‐DD and AT1R‐CC genotype
Number of subjects: 885

Group type: COMPARATOR
Intervention: Other genotype combinations
Number of subjects: 885
Study: 9337498

Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 80
Study: 7523906

Group type: EXPERIMENTAL
Intervention: X-ray-induced micronuclei (MN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV-induced unscheduled DNA synthesis (UDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous micronuclei (MN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous unscheduled DNA synthesis (UDS)
Number of subjects: 0
Study: 3408653

Group type: EXPERIMENTAL
Intervention: Philips TL‐01 lamp
Number of subjects: 10

Group type: COMPARATOR
Intervention: Philips TL‐12 lamp
Number of subjects: 10
Study: 31959171

Group type: EXPERIMENTAL
Intervention: Urination during flexible cystoscopy
Number of subjects: 96

Group type: COMPARATOR
Intervention: No urination during flexible cystoscopy (Control)
Number of subjects: 96
Study: 31619196

Group type: EXPERIMENTAL
Intervention: Face-to-face MBI + TAU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Internet-delivered MBI + TAU
Number of subjects: 120

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 120
Study: 28560612

Group type: EXPERIMENTAL
Intervention: Higher daily stress
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Access to social support
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Healthcare utilization (asthma-specific factor)
Number of subjects: 276
Study: 25527661

Group type: EXPERIMENTAL
Intervention: Protein intake ranging from 0.22 to 2.56 g · kg(‐1) · d(‐1) during early gestation.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Protein intake ranging from 0.22 to 2.56 g · kg(‐1) · d(‐1) during late gestation.
Number of subjects: 29
Study: 23692953

Group type: EXPERIMENTAL
Intervention: Multimedia patient education program with trained health professional follow-up
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1206
Study: 21338298

Group type: EXPERIMENTAL
Intervention: Peer disclosing interviewers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer non-disclosing interviewers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-peer interviewers
Number of subjects: 0
Study: 19037813

Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) lubricant eyedrops
Number of subjects: 50250

Group type: EXPERIMENTAL
Intervention: Leucyl-histidylhydrazide peptidomimetic
Number of subjects: 50250

Group type: EXPERIMENTAL
Intervention: L-carnosine
Number of subjects: 50250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50250
Study: 17716321

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into frontal (10 U)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into temporal (6 U)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into glabellar (9 U)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injection into all three areas (total dose 25 U)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 16277296

Group type: EXPERIMENTAL
Intervention: Speed discrimination task with first-order drifting luminance gratings at reference speeds of 2 and 8 deg/s, stimulus durations of 500 ms and 1000 ms
Number of subjects: 33

Group type: COMPARATOR
Intervention: Older age group (mean age 71 years)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Older women in the older age group
Number of subjects: 33
Study: 12015496

Group type: EXPERIMENTAL
Intervention: Early feeding regimen (group B) - clear fluids on the first postoperative day, regular diet after tolerating 500 mL of clear fluids.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Traditional feeding group (group A) - nothing by mouth until bowel function documented, then advanced slowly to solid diet.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 96
Study: 10468076

Group type: EXPERIMENTAL
Intervention: Adenosine (140 microg/kg/min x 6 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adenosine combined with limited exercise (140 microg/kg/min x 4 minutes during 6 minutes of modified Bruce treadmill exercise)
Number of subjects: 32
Study: 7601918

Group type: EXPERIMENTAL
Intervention: Collagen membrane applied at experimental sites
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control sites (no collagen barrier)
Number of subjects: 14
Study: 1969560

Group type: EXPERIMENTAL
Intervention: Elemental diet ('Vivonex')
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polymeric diet ('Fortison')
Number of subjects: 30
Study: 7004038

Group type: EXPERIMENTAL
Intervention: Type I programme (square waves, 12 U/hr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Type II programme (boluses, 120 U/hr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Closed-loop programme
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Type I programme
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Type II programme
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Boluses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Square waves
Number of subjects: 10
Study: 31718959

Group type: EXPERIMENTAL
Intervention: Silica particles air‐abrasion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cleaning with 70% alcohol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: No bonding agent
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Monobond Plus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RelyX Ceramic Primer
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single Bond Universal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pre‐treatments
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bonding agent
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interaction of pre‐treatments and bonding agent
Number of subjects: 36
Study: 30521105

Group type: EXPERIMENTAL
Intervention: Probiotic combination
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 28595137

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control (chemotherapy without cetuximab)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: BRAF-mutated tumours
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: High serum IL-6 or CRP levels
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Reduction in IL-6 and CRP levels
Number of subjects: 512
Study: 26645895

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 779
Study: 23989460

Group type: EXPERIMENTAL
Intervention: Provocative discography screening prior to surgery
Number of subjects: 310

Group type: COMPARATOR
Intervention: No discography screening prior to surgery
Number of subjects: 310
Study: 22133964

Group type: EXPERIMENTAL
Intervention: 2.5° distal root tipping bend for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15° distal root tipping bend for 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of areas under pressure vs tension
Number of subjects: 15
Study: 19405857

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 16780556

Group type: EXPERIMENTAL
Intervention: 3 MU IFN + ribavirin for 12 months (Group 1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 5 MU IFN + ribavirin for 12 months (Group 2)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 3 MU IFN + ribavirin for 6 months (Group 3)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 5 MU IFN + ribavirin for 6 months (Group 4)
Number of subjects: 97
Study: 14769600

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Vitrectomy plus autologous serum
Number of subjects: 185

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 185
Study: 11387289

Group type: EXPERIMENTAL
Intervention: Athletes with varicocele
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-athletes with varicocele
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study: 9401097

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (50 mg) taken orally t.i.d. with food
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8285334

Group type: EXPERIMENTAL
Intervention: 0.5% 2-chloroprocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% prilocaine
Number of subjects: 60
Study: 3620281

Group type: EXPERIMENTAL
Intervention: 0.8 g kg‐1 absolute ethanol orally
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 24
Study: 29699852

Group type: EXPERIMENTAL
Intervention: Needle-free device
Number of subjects: 57

Group type: COMPARATOR
Intervention: SC injection
Number of subjects: 57
Study: 27289107

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (physical training, cognitive behavioural training, participatory ergonomics)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 594
Study: 24387916

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 21
Study: 22435889

Group type: EXPERIMENTAL
Intervention: Video-conferencing with family caregiver participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard meetings without family caregiver participation
Number of subjects: 0
Study: 21256028

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training 3×/week
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional dose of vitamin D (880 IU/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: High dose of vitamin D (1600 IU/d)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vitamin D supplementation (both doses)
Number of subjects: 113
Study: 19228852

Group type: EXPERIMENTAL
Intervention: Vitamin therapy (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12)
Number of subjects: 5522

Group type: EXPERIMENTAL
Intervention: Vitamin therapy
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study: 16857528

Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard care condition
Number of subjects: 288
Study: 14694031

Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wide-field multifocal electroretinogram (WF-mfERG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (never received vigabatrin)
Number of subjects: 32
Study: 10682411

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse (Corsodyl)
Number of subjects: 12
Study: 9493651

Group type: EXPERIMENTAL
Intervention: BALF-PIIINP
Number of subjects: 77

Group type: COMPARATOR
Intervention: S-PIIINP
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BALF-PICP
Number of subjects: 77

Group type: COMPARATOR
Intervention: S-PICP
Number of subjects: 77

Group type: COMPARATOR
Intervention: S-ACE
Number of subjects: 77

Group type: COMPARATOR
Intervention: S-IL-2R
Number of subjects: 77
Study: 7839898

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 intravenously (i.v.) on day 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside 100 mg/m2 subcutaneously (sc) 12 hourly for days 1‐5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of i.v. cyclophosphamide 600 mg/m2 on day 1 and cytosine arabinoside 100 mg/m2 12 hourly sc for days 1‐5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of cytosine arabinoside and cyclophosphamide
Number of subjects: 60
Study: 3128161

Group type: EXPERIMENTAL
Intervention: Corn oil diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-modified diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 0
Study: 29720037

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 27578132

Group type: EXPERIMENTAL
Intervention: MUFA-enriched diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: PUFA-enriched diet
Number of subjects: 39
Study: 26637992

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenously applied prostacyclin and bisphosphonate
Number of subjects: 40
Study: 23778009

Group type: EXPERIMENTAL
Intervention: Candesartan with amlodipine
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Candesartan with non-amlodipine CCBs
Number of subjects: 2049
Study: 20565392

Group type: EXPERIMENTAL
Intervention: 0.568 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.136 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Number of subjects: 0
Study: 18416074

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with spinal Tui Na
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 30
Study: 16943467

Group type: EXPERIMENTAL
Intervention: Continuous infusion of levobupivacaine 0.25% at a rate of 5 ml per hour after an initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Number of subjects: 16
Study: 12948312

Group type: EXPERIMENTAL
Intervention: Small capsulorhexis (4.5 to 5.0 mm)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Large capsulorhexis (6.0 to 7.0 mm)
Number of subjects: 367
Study: 10223022

Group type: EXPERIMENTAL
Intervention: Tailored health messages
Number of subjects: 272

Group type: COMPARATOR
Intervention: Personalized health messages
Number of subjects: 272

Group type: COMPARATOR
Intervention: General health messages
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 272
Study: 8571186

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis
Number of subjects: 20

Group type: COMPARATOR
Intervention: No heparin prophylaxis
Number of subjects: 20
Study: 1914626

Group type: EXPERIMENTAL
Intervention: Maternal social support provided by trained volunteer coaches during prenatal and postpartum periods
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control condition (no maternal social support)
Number of subjects: 46
Study: 7259512

Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride (5 mg/kg intermittent IV bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride (0.5 mg/kg/min constant infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No calcium chloride (control)
Number of subjects: 0
Study: 30703519

Group type: EXPERIMENTAL
Intervention: Down-regulation neurofeedback (NF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Up-regulation neurofeedback (NF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Neurofeedback training
Number of subjects: 56
Study: 28233942

Group type: EXPERIMENTAL
Intervention: Just-in-time feedback targeting a 25% reduction in chew counts
Number of subjects: 18

Group type: COMPARATOR
Intervention: Baseline chew count
Number of subjects: 18
Study: 26067186

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sitagliptin 25 mg once daily
Number of subjects: 148
Study: 23988802

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid injection of 80 mg methylprednisolone acetate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Epidural corticosteroid injection of 40 mg methylprednisolone acetate
Number of subjects: 42
Study: 21131336

Group type: EXPERIMENTAL
Intervention: Sliding rehabilitation machine training (2 weeks) followed by conventional training (2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional training only
Number of subjects: 30
Study: 19297384

Group type: COMPARATOR
Intervention: Increasing education categories
Number of subjects: 27207

Group type: COMPARATOR
Intervention: Increasing income categories
Number of subjects: 27207
Study: 18037652

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103
Study: 15136320

Group type: EXPERIMENTAL
Intervention: High-dose antioxidants
Number of subjects: 4753

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 4753

Group type: EXPERIMENTAL
Intervention: Visual acuity worse than 20/40 in 1 eye
Number of subjects: 4753

Group type: EXPERIMENTAL
Intervention: Nuclear opacity
Number of subjects: 4753

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 4753